BACE Inhibitor Atabecestat Trial in Pre-Symptomatic Alzheimer's Risk Terminated Early
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
Summary
This phase 2/3 clinical trial tested atabecestat, a BACE1 inhibitor designed to reduce amyloid production, in 557 cognitively normal adults who tested positive for amyloid — meaning they were biologically at risk for Alzheimer's disease but had no symptoms yet. The trial compared two doses (5 mg and 25 mg) against placebo, measuring cognitive change using the Preclinical Alzheimer Cognitive Composite (PACC). The study was terminated early in 2018 before its planned completion. Early termination of BACE inhibitor trials has been linked to liver toxicity signals and paradoxical cognitive worsening in related compounds. This trial represented one of the earliest large attempts to intervene in Alzheimer's disease before symptoms appear, targeting the amyloid pathway at its earliest detectable biological stage.
Detailed Summary
Alzheimer's disease develops over decades before symptoms appear, and the window of opportunity for intervention may be widest in cognitively normal individuals who already show amyloid accumulation in the brain. This trial attempted to capitalize on that window by testing whether a BACE1 inhibitor could slow or prevent cognitive decline in people who are biologically at risk but not yet symptomatic.
Atabecestat is an oral BACE1 inhibitor developed by Janssen Research & Development. BACE1 is an enzyme responsible for the first cleavage step in amyloid precursor protein processing, which ultimately generates amyloid-beta peptides that aggregate into plaques. By blocking this enzyme, atabecestat aimed to reduce amyloid production upstream, before plaques could accumulate further.
The trial enrolled 557 amyloid-positive, asymptomatic participants across two active dose arms (5 mg and 25 mg) and a placebo arm. The primary efficacy measure was the Preclinical Alzheimer Cognitive Composite (PACC), a sensitive battery designed to detect subtle cognitive changes in preclinical populations. The study was sponsored by Janssen and registered in 2015 with an original completion target of late 2018.
The trial was terminated early, a pattern that plagued nearly the entire BACE inhibitor drug class. Other BACE inhibitors — including verubecestat, lanabecestat, and elenbecestat — were also halted due to either lack of efficacy, cognitive worsening signals, or hepatotoxicity concerns. Atabecestat was specifically associated with liver enzyme elevations that triggered safety reviews.
The implications are sobering for amyloid-targeting strategies using BACE inhibition. While the biology of targeting amyloid in presymptomatic stages remains scientifically sound, the execution via BACE1 inhibitors appears fraught with off-target effects. The field has since pivoted toward anti-amyloid antibodies, with lecanemab and donanemab showing more promise in early symptomatic stages.
Key Findings
- Trial was terminated early; atabecestat was associated with hepatotoxicity signals across the BACE inhibitor class.
- Targeted amyloid-positive, cognitively normal adults — one of the earliest preclinical Alzheimer's prevention designs.
- Used the PACC composite, a sensitive tool built specifically for detecting subtle cognitive change before symptom onset.
- Two doses tested (5 mg and 25 mg) versus placebo in a phase 2/3 adaptive design enrolling 557 participants.
- Failure mirrors broader collapse of BACE inhibitor class, prompting shift toward anti-amyloid antibody therapies.
Methodology
This was a randomized, placebo-controlled, double-blind phase 2/3 trial in amyloid-positive cognitively normal adults, using two active doses of atabecestat versus placebo. The primary endpoint was change on the Preclinical Alzheimer Cognitive Composite (PACC). The trial was terminated early in 2018 before reaching its planned completion date.
Study Limitations
The summary is based on the abstract and ClinicalTrials.gov registration only — full efficacy and safety results are not available in this source. Early termination means the trial was likely underpowered to detect cognitive effects, and the reasons for termination (safety vs. futility) cannot be fully confirmed from available data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.